Rhythm Pharmaceuticals, Inc.
RYTM
$96.22
-$1.70-1.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 156.29M | 136.86M | 130.13M | 112.53M | 101.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 156.29M | 136.86M | 130.13M | 112.53M | 101.78M |
| Cost of Revenue | 16.81M | 14.21M | 13.37M | 12.82M | 11.40M |
| Gross Profit | 139.48M | 122.65M | 116.76M | 99.72M | 90.38M |
| SG&A Expenses | 158.54M | 149.01M | 144.30M | 138.55M | 133.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 333.73M | 309.49M | 303.23M | 285.65M | 274.97M |
| Operating Income | -177.44M | -172.62M | -173.11M | -173.12M | -173.18M |
| Income Before Tax | -183.08M | -168.57M | -260.22M | -258.28M | -258.09M |
| Income Tax Expenses | -17.00K | 125.00K | 345.00K | 631.00K | 1.34M |
| Earnings from Continuing Operations | -183.06 | -168.69 | -260.57 | -258.91 | -259.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -183.06M | -168.69M | -260.57M | -258.91M | -259.43M |
| EBIT | -177.44M | -172.62M | -173.11M | -173.12M | -173.18M |
| EBITDA | -175.91M | -171.08M | -171.54M | -171.52M | -171.53M |
| EPS Basic | -3.02 | -2.82 | -4.36 | -4.34 | -4.37 |
| Normalized Basic EPS | -1.83 | -1.80 | -1.81 | -1.81 | -1.83 |
| EPS Diluted | -3.02 | -2.82 | -4.36 | -4.34 | -4.37 |
| Normalized Diluted EPS | -1.83 | -1.80 | -1.81 | -1.81 | -1.83 |
| Average Basic Shares Outstanding | 249.56M | 246.89M | 243.97M | 241.59M | 238.24M |
| Average Diluted Shares Outstanding | 249.56M | 246.89M | 243.97M | 241.59M | 238.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |